GB2299121B
(en)
*
|
1995-03-24 |
1999-02-24 |
Peter Woodhead |
Improvements in or relating to security apparatus
|
AU1463097A
(en)
|
1996-01-04 |
1997-08-01 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(en)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
COMPOSITIONS OF ASSISTANTS.
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
CN1798548B
(en)
|
2003-06-02 |
2010-05-05 |
诺华疫苗和诊断公司 |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
JP4993750B2
(en)
|
2005-01-27 |
2012-08-08 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
ES2557282T3
(en)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use
|
KR101644221B1
(en)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 PEPTIDE VACCINE
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
RU2518291C2
(en)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Antigen tau-peptides and their application
|
MY163512A
(en)
|
2009-09-03 |
2017-09-15 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
RU2581020C2
(en)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Vaccine compositions
|
WO2011126863A1
(en)
|
2010-03-30 |
2011-10-13 |
Children's Hospital & Research Center Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
PE20142406A1
(en)
|
2012-05-04 |
2015-01-23 |
Pfizer |
ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
IL296681B2
(en)
|
2014-01-21 |
2024-09-01 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
CN107427568B
(en)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
Immunogenic compositions for use in pneumococcal vaccines
|
GB2534933A
(en)
*
|
2015-02-06 |
2016-08-10 |
Duraflex Ltd |
Glazing bead
|
AU2016271857B2
(en)
|
2015-06-03 |
2020-05-28 |
Affiris Ag |
IL-23-P19 vaccines
|
CN107849119A
(en)
|
2015-07-07 |
2018-03-27 |
阿费里斯股份公司 |
For the vaccine for the disease for treating and preventing IgE mediations
|
PE20240927A1
(en)
|
2015-07-21 |
2024-04-30 |
Pfizer |
IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS THAT COMPRISE THEM AND THEIR USES
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
PL3570879T3
(en)
|
2017-01-20 |
2022-06-20 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(en)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
Method for purifying bacterial polysaccharides
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP4093873A4
(en)
|
2020-01-24 |
2024-07-10 |
Aim Immunotech Inc |
Methods, compositions, and vaccines for treating a virus infection
|
BR112022015796A2
(en)
|
2020-02-21 |
2022-10-11 |
Pfizer |
PURIFICATION OF SACCHARIDES
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
JP2023549736A
(en)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
CA3211240A1
(en)
|
2021-02-19 |
2022-08-25 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
WO2022249107A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP4346892A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2022391752A1
(en)
|
2021-11-18 |
2024-06-13 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
IL314243A
(en)
|
2022-01-13 |
2024-09-01 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024166008A1
(en)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|